伏立康唑对侵袭性肺曲霉病患者细胞因子及肺纤维化的影响-国际临床研究杂志-CSCIED科技核心评价数据库-手机版

伏立康唑对侵袭性肺曲霉病患者细胞因子及肺纤维化的影响

Effects of voriconazole on cytokines and pulmonary fibrosis in patients with invasive pulmonary aspergillosis

ES评分 0 浏览量：779 下载量：0

DOI	10.12208/j.ijcr.20220332
刊名	国际临床研究杂志 International Journal of Clinical Research
年，卷(期)	2022, 6(7)
作者	杜振雄*,唐开华,梁秋,刘绍德,
作者单位	广西柳钢医疗有限公司医院广西柳州 ; ;
摘要	侵袭性肺曲霉病主要发生于免疫功能低下的患者。伏立康唑属于第二代三唑类抗真菌药物具有较强的抗菌效果，对曲霉菌具有较好的抗菌活性，在侵袭性肺曲霉病治疗中发挥着重要的作用。侵袭性肺曲霉病患者体内存在明显的炎症反应，同时因为免疫功能低下免疫因子水平发生改变，局部侵袭性肺曲霉病中的慢性空洞性肺曲霉病若未得到治疗可引起肺纤维化。为进一步探究、总结伏立康唑用于治疗侵袭性肺曲霉病的肺抗菌性作用，可从对细胞因子及肺纤维的影响进行分析。
Abstract	Invasive pulmonary aspergillosis mainly occurs in immunocompromised patients. Voriconazole is a second-generation triazole antifungal drug with strong antibacterial effect and good antibacterial activity against Aspergillus, which plays an important role in the treatment of invasive pulmonary aspergillosis. Patients with invasive pulmonary aspergillosis have obvious inflammatory responses, and because of the altered levels of immune factors in the immunocompromised, chronic cavitary pulmonary aspergillosis in local invasive pulmonary aspergillosis can cause pulmonary fibrosis if left untreated. To further explore and summarize the pulmonary antibacterial effect of voriconazole in the treatment of invasive pulmonary aspergillosis, the effects on cytokines and pulmonary fibers can be analyzed.
关键词	伏立康唑；侵袭性肺曲霉病；细胞因子；肺纤维化
KeyWord	Voriconazole; Invasive Pulmonary Aspergillosis; Cytokines; Pulmonary Fibrosis
基金项目
页码	141-143

参考文献
相关文献

[1] 李兰娟,任红主编.传染病学第9版[M].北京:人民卫生出版社, 2018:237.

[2] 李敏,周丽娟,张华,等.CYP2C19基因多态性对侵袭性真菌感染患者伏立康唑用药的指导意义探讨[J].中国医院药学杂志,2020,40(2):156-160,207.

[3] 孟帅.伏立康唑治疗慢性阻塞性肺疾病合并侵袭性肺曲霉菌病的临床研究[J].山西医药杂志, 2020, 49(3): 282-284.

[4] 陈炆颖.伏立康唑治疗COPD伴肺曲霉菌病的效果及对炎性因子的影响[J].北方药学,2021,18(1):159-160.

[5] 赵燕,饶爱华,孙密芬,等.伏立康唑和伊曲康唑治疗血液恶性肿瘤继发真菌感染的临床疗效及对血清炎症因子的作用[J].中华医院感染学杂志,2018,28(05): 703-706, 714.

[6] 袁震,杨海平,马晓艳,等.肝衰竭并发肺部真菌感染患者病原菌分布及伏立康唑治疗后免疫功能改变分析[J].肝脏,2021,26(12):1374-1377,1386.

[7] 段旺旺,雷杰喻,白延宁,等伏立康唑与胸腺肽a1联合治疗老年COPD合并侵袭性肺曲霉菌病的临床效果[J].贵州医药,2021,45(11):1719-1720.

[8] patients with a special focus on Scedosporium species罗霄云,申琳.伏立康唑联合胸腺肽α1对老年COPD合并侵袭性肺真菌病患者的影响[J].中国合理用药探索,2020,17(7):70-73.

[9] Denning D W, Cadranel J, Beigelman-Aubry C , et al. Chronic pulmonary aspergillosis: Rationale and clinical guidelines for diagnosis and management[J]. European Respiratory Journal, 2015, 47(1):45-68.

[10] Kosmidis C, Newton P, Muldoon E G , et al. Chronic fibrosing pulmonary aspergillosis: a cause of 'destroyed lung' syndrome.[J]. Scandinavian Journal of Infectious Diseases, 2017, 49(4):296-301.

[11] 张贵宁,危之屏,叶明霞.伏立康唑雾化吸入对侵袭性肺曲霉病患者细胞因子及肺纤维化的影响[J].海南医学,2015,26(6):787-789,790.

[12] Hassanzad M, Mortezaee V , Bongomin F , et al. in a cystic fibrosis patient with short-term adjunctive therapy with voriconazole: A case report[J]. Journal de Mycologie Médicale/Journal of Medical Mycology, 2019,29(2): 189-192.

Hedayati M T, Tavakoli M, Maleki M, et al. Fungal epidemiology in cystic fibrosis complex[J]. Microbial Pathogenesis, 2019，129:168-175.

引用本文

杜振雄*,唐开华,梁秋,刘绍德. 伏立康唑对侵袭性肺曲霉病患者细胞因子及肺纤维化的影响 [J]. 国际临床研究杂志. 2022; 6; (7). 141 - 143.

文献评论

相关学者

相关机构